Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$68.12 USD
+1.62 (2.44%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $68.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.12 USD
+1.62 (2.44%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $68.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Zacks News
Here's How Much a $1000 Investment in Edwards Lifesciences Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
4 GARP Stocks to Scoop Up for Maximum Returns
by Shilpa Mete
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RACE, GWW, ALLE and EW are some stocks that hold promise.
Implied Volatility Surging for Edwards Lifesciences (EW) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Edwards Lifesciences (EW) stock based on the movements in the options market lately.
Edwards Lifesciences' (EW) TMTT Sales Aid Amid Margin Woes
by Zacks Equity Research
Edwards Lifesciences (EW) continues to expect the global TAVR opportunity to increase to $10 billion by 2028.
Here's Why You Should Invest in Edward Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business and the Critical Care segment.
Edwards Lifesciences (EW) Down 5.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Stock Reports for Home Depot, Linde & Walt Disney
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Linde plc (LIN) and The Walt Disney Company (DIS).
Edwards Lifesciences' (EW) TAVR Study Outcome Favorable
by Zacks Equity Research
Edwards Lifesciences' (EW) latest findings of the study confirm the value of the Edwards Benchmark programme for standardizing clinical pathways for patients undergoing TAVR in Europe.
ITGR vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
STERIS (STE) Q4 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
Heading into fiscal 2024, STERIS (STE) expects many of its fiscal 2023 challenges to abate, including procedure volumes and supply chain constraints.
Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amid a challenging economic environment, Haemonetics (HAE) delivers impressive fiscal fourth-quarter organic revenues, led by the stellar performance across the Plasma and Hospital business.
Alcon (ALC) Q1 Earnings Surpass Estimates, 23' EPS View Up
by Zacks Equity Research
Alcon (ALC) Q1 revenues were driven by strong consumables and equipment sales.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) on consistent partnership growth and a strong focus on strategic execution.
Charles River (CRL) Q1 Earnings Top Estimates, View Narrowed
by Zacks Equity Research
Charles River (CRL) registers robust growth in small research models, research model services and the Cell Solutions business.
NuVasive (NUVA) Q1 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
NuVasive's (NUVA) strong sales across the U.S. Spinal Hardware and U.S. Surgical Support businesses instill optimism.
Syneos Health (SYNH) Tops Q1 Earnings, Announces Merger Plan
by Zacks Equity Research
Syneos Health's (SYNH) first-quarter 2023 earnings and revenues beat estimates. The company enters into a definitive merger agreement to be acquired by a private investment consortium.
SmileDirectClub (SDC) Q1 Earnings Miss, Gross Margin Up
by Zacks Equity Research
SmileDirectClub (SDC) Q1 revenues are affected by persistent macroeconomic headwinds.
Exact Sciences (EXAS) Q1 Earnings Top, Sales View Raised
by Zacks Equity Research
The upside in Exact Sciences' (EXAS) screening revenues is primarily coming from broad-based momentum in Cologuard adoption.
Henry Schein (HSIC) Q1 Earnings Miss, Operating Margin Dips
by Zacks Equity Research
Henry Schein's (HSIC) first-quarter results largely reflect lower contributions from the sales of PPE products and COVID-19 test kits.
Omnicell's (OMCL) New Acquisitions Aid Growth, Cost Woes Stay
by Zacks Equity Research
Omnicell (OMCL) remains well-positioned to meet pharmacy and hospital needs, backed by the recent acquisitions and expansion of its advanced services solutions.
Bruker's (BRKR) New Buyout to Advance Digital Transformation
by Zacks Equity Research
Bruker's (BRKR) IDS division expands its unique vendor-agnostic software solutions portfolio by integrating ZONTAL with the Mestrelab Research and Arxspan scientific software solutions.
Here's Why You Should Retain Abbott (ABT) Stock For Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.
Teleflex (TFX) Q1 Earnings Top Estimates, 2023 Sales View Up
by Zacks Equity Research
Teleflex (TFX) registers growth across the majority of its businesses, including double-digit increases in interventional and surgical revenues in Q1.
Globus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips
by Zacks Equity Research
The significant year-over-year surge in Globus Medical's (GMED) Enabling Technologies sales is driven by ongoing demand for the company's robotics and imaging system technologies.
Insulet (PODD) Q1 Earnings Beat Estimates, Sales View Up
by Zacks Equity Research
Omnipod 5 continues to be a driving force of Insulet's (PODD) strong U.S. growth, representing almost 95% of U.S. new customer starts in the first quarter.